# Bio-Link

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bio-link

- Industry: Medical Devices & Equipment
- Headquarters: Shanghai, China
- Website: www.biolink.com.cn
- Latest round: Series A (Feb 20, 2023)
- Investors on record: 7

## About

Based in Shanghai, China, and founded in 2021, Bio-Link is a pharmaceutical equipment company that provides process solutions for the field of life sciences. It has five production bases and more than 10 sales service points in Beijing, Guangzhou, Chengdu, and other places. In addition, the branches have opened in Germany and Singapore. In January 2024, Verdot established a partnership with the company. In February 2024, Bio-Link closed a series A+ funding. In November 2024, the firm closed a venture funding.

The company is committed to the manufacture of process equipment and consumables in the production engineering of recombinant protein drugs, vaccines, antibody drugs, and other biological products. The products can be categorized into cell culture, fluid management, process filtration, and other series. It also offers quality control and validation analysis solutions for biopharmaceutical consumables.

The company’s revenue is generated by providing medical process equipment and consumables.

The company will use the funding for market expansion and product research and development.

## Funding rounds

- Series A, Feb 20, 2023 — Cathay Capital, Boyu Capital, CanSino Biologics Inc., Apricot Capital, Tsing Song Capital, Sino Biological Inc., Suzhou Xinhui Boan Enterprise Management

## Investors

- Cathay Capital — Series A
- Boyu Capital (https://capitalatlas.ai/funds/boyu-capital) — Series A
- CanSino Biologics Inc. — Series A
- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Series A
- Tsing Song Capital (https://capitalatlas.ai/funds/tsing-song-capital) — Series A
- Sino Biological Inc. — Series A
- Suzhou Xinhui Boan Enterprise Management — Series A